Revised: 8 December 2023

Committees

Recent New Zealand Gazette Notices Relating to Classification

TThe most recent update to the First Schedule to the Medicines Regulations 1984, Medicines Amendment Regulations (No 2) 2021, came into effect on 30 August 2021. Please note that Gazette notices published after 30 August 2021 (listed above) need to be taken into account when seeking the classification of a medicine. .

The current classification of a medicine may also be found in the Classification Database.

2023

    2022

    2021

    2020

    2019

    4 December 2023 (2023-go5620)

    Restricted Medicines

    Methenamine hippurate

    3 November 2023 (2023-go4878)

    Prescription Medicines

    Alanylglutamine

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council

    Amivantamab

    Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose

    Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council

    Asciminib

    Atogepant

    Avacopan

    Avalglucosidase alfa

    Belumosudil

    Belzutifan

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council

    Bilastine; except when specified elsewhere in this schedule

    Body Protective Compound –157

    Bufexamac

    Cannabidiol; except when elsewhere in the schedule

    Cardarine

    Cariprazine

    Casirivimab

    Cemiplimab

    Cilgavimab

    Ciltacabtagene autoleucel

    Deucravacitinib

    Deutetrabenazine

    Diroximel fumarate

    Dostarlimab

    Edaravone

    Elexacaftor

    Enfortumab vedotin

    Eslicarbazepine

    Estetrol monohydrate

    Etesevimab

    Faricimab

    Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council

    Fenbendazole

    Filgotinib

    Finerenone

    Fostemsavir

    Fruquintinib

    Ganaxolone

    Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council

    Glofitamab

    Hyaluronidase

    Icosapent ethyl

    Imdevimab

    Inclisiran

    Infigratinib

    Lemborexant

    Lenacapavir

    Levomefolic acid; for injection.

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule

    Lurbinectedin

    Luspatercept

    Mavacamten

    Mobocertinib

    Molnupiravir; except when specified elsewhere in this schedule

    Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use

    Nirmatrelvir; except when specified elsewhere in this schedule

    Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections

    Onasemnogene abeparvovec

    Opicapone

    Osilodrostat

    Patisiran

    Pegcetacoplan

    Pegvaliase

    Pemigatinib

    Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council

    Ponesimod

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council

    Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course)

    Regdanvimab

    Relugolix

    Ripretinib 

    Risdiplam

    Ritonavir; except when specified elsewhere in this schedule

    Sacituzumab govitecan

    Selinexor

    Selumetinib

    Somapacitan

    Sotorasib

    Sotrovimab

    Teneligliptin

    Tepotinib

    Tirzepatide

    Tislelizumab

    Tixagevimab

    Trabectedin

    Trastuzumab deruxtecan

    Trifarotene

    Vericiguat

    Vosoritide

    Zanubrutinib

    Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations

    Restricted Medicine

    Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council

    Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist

    Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age

    Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age

    Molnupiravir; for use in the treatment of COVID-19

    Nirmatrelvir; for use in the treatment of COVID-19

    Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine

    Ritonavir; for use in the treatment of COVID-19

    Pharmacy-only Medicines

    Bilastine; for oral use

    Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose

    Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose

    Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose

    17 October 2023 (2023-go4878)

    Prescription Medicines

    Cannabidiol; except when elsewhere in the schedule.

    Restricted Medicines

    Cannabidiol; when supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer’s original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist.

    6 September 2023 (2023-go4130)

    Prescription Medicines

    Asciminib

    Atogepant

    Avacopan

    Avalglucosidase alfa

    Bilastine; except when specified elsewhere in this Schedule.

    Body Protective Compound –157

    Deucravacitinib

    Edaravone

    Fruquintinib

    Ganaxolone

    Glecaprevir; except when supplied in combination with pibrentasvir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council.

    Glofitamab

    Lenacapvir

    Mobocertinib

    Osilodrostat

    Patisiran

    Pemigatinib

    Pibrentasvir; except when supplied in combination with glecaprevir in a manufacturer’s original pack that has received consent from the Minister of Health or Director General for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of an approved training programme, when provided by nurses who meet the requirements of the Nursing Council or pharmacists who meet the requirements of the Pharmacy Council.

    Relugolix

    Teneligliptin

    Tirzepatide

    Tislelizumab

    Vosoritide

    Zinc; except for internal use in medicines containing 25 milligrams or less per recommended daily dose; except for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose in packs that have received the consent of the Minister or the Director-General to their distribution as general sale medicines, when sold in the manufacturer’s original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except for external use except when specified elsewhere in this schedule; except in parenteral nutrition replacement preparations.

    Pharmacy-only Medicines

    Bilastine; for oral use.

    Medicines for General Sale

    Zinc; for external use except zinc chloride in medicines containing more than 5%; for internal use in medicines containing 25 milligrams or less per recommended daily dose; for internal use in medicines containing 50 milligrams or less and more than 25 milligrams per recommended daily dose and in packs which have received the consent of the Minister or the Director-General to their distribution as general sale medicines and that are sold in the manufacturer's original pack and when labelled with a statement that the product may be dangerous if taken in large amounts or for long periods; except in parenteral nutrition replacement preparations.

    16 August 2023 (2023-go3765)

    Prescription Medicines

    Naloxone; except when provided as part of an approved emergency kit for the treatment of opioid overdose; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those authorised by regulation 3, 4 or 5 of the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.

    24 May 2023 (2023-go2081)

    Prescription Medicines

    Fenbendazole

    Glecaprevir; except when supplied in combination with pibrentasvir for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of the approved training programme, when provided by nurses who meet the requirements of the Nursing Council.

    Pibrentasvir; except when supplied in combination with glecaprevir for treatment of chronic hepatitis C virus infection to people who meet the clinical and eligibility criteria of the approved training programme, when provided by nurses who meet the requirements of the Nursing Council.

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist, or oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when specified elsewhere in this schedule except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule.

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.

    Articaine; except when used as a local anaesthetic in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.

    Felypressin; except when combined with a local anaesthetic and used in practice by a dental therapist, oral health therapist or dental hygienist (without local anaesthetic exclusion on their scope of practice) registered with the Dental Council.

    Dostarlimab

    Diroximel fumarate

    Infigratinib

    Ponesimod

    Selinexor

    Selumetinib

    Sotorasib

    Tepotinib

    Belzutifan

    Enfortumab vedotin

    Lurbinectedin

    Mavacamten

    Somapacitan

    Restricted Medicines

    Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less; except in medicines for injection containing 0.1% for use in practice in an emergency by a dental therapist, an oral health therapist or a dental hygienist registered with the Dental Council.

    4 May 2023 (2023-go1686)

    Prescription Medicines

    Cardarine

    Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.

    Ripretinib

    Faricimab

    Deutetrabenazine

    Eslicarbazepine

    Lemborexant

    Luspatercept

    Trabectedin

    Molnupiravir; except when specified elsewhere in this schedule

    Nirmatrelvir; except when specified elsewhere in this schedule

    Ritonavir; except when specified elsewhere in this schedule

    Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).

    Alanylglutamine

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Cariprazine

    Casirivimab

    Cemiplimab

    Cilgavimab

    Elexacaftor

    Etesevimab

    Filgotinib

    Hyaluronidase

    Imdevimab

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Onasemnogene abeparvovec

    Opicapone

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Regdanvimab

    Risdiplam

    Sotrovimab

    Tixagevimab

    Trifarotene

    Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.

    Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.

    Levomefolic acid; for injection.

    Amivantamab

    Glu-urea-Lys(ahx)-hbed-CC

    Icosapent ethyl

    Zanubrutinib

    Faricimab

    Ciltacabtagene autoleucel

    Belumosudil

    Estetrol monohydrate

    Finerenone

    Fostemsavir

    Inclisiran

    Pegcetacoplan

    Pegvaliase

    Sacituzumab govitecan

    Trastuzumab deruxtecan

    Vericiguat

    Bufexamac

    Restricted Medicines

    Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.

    Molnupiravir; for use in the treatment of COVID-19

    Nirmatrelvir; for use in the treatment of COVID-19

    Ritonavir; for use in the treatment of COVID-19

    Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine.

    Schedule 3

    Pharmacy-only Medicines

    Folic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Folinic acid; For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age.

    1 May 2023 (2023-go1592)

    Pharmacy-only Medicines

    Choline Salicylate; in medicines containing 10% or less and in packs sizes of 15 grams or less when indicated for use in children under 18 months of age.

    1 December 2022 (2022-go5214)

    Restricted Medicines

    Pholcodine; in medicines for oral use containing not more than 15 milligrams of pholcodine per solid dosage unit or per dose of liquid with a maximum daily dose not exceeding 100 milligrams of pholcodine, when combined with 1 or more active ingredients in such a way that the substance cannot be recovered by readily applicable means, or in a yield that would constitute a risk to health, when sold in a pack approved by the Minister or the Director-General for distribution as a restricted medicine.

    4 November 2022 (2022-go4713)

    Prescription Medicines

    Cardarine

    Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.

    Ripretinib

    Faricimab

    Deutetrabenazine

    Eslicarbazepine

    Lemborexant

    Luspatercept

    Trabectedin

    Molnupiravir; except when specified elsewhere in this schedule

    Nirmatrelvir; except when specified elsewhere in this schedule

    Ritonavir; except when specified elsewhere in this schedule

    Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).

    Alanylglutamine

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Cariprazine

    Casirivimab

    Cemiplimab

    Cilgavimab

    Elexacaftor

    Etesevimab

    Filgotinib

    Hyaluronidase

    Imdevimab

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Onasemnogene abeparvovec

    Opicapone

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Regdanvimab

    Risdiplam

    Sotrovimab

    Tixagevimab

    Trifarotene

    Nitrofurantoin; except when supplied for oral use containing 100mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16–65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.

    Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.

    Levomefolic acid; for injection.

    Amivantamab

    Glu-urea-Lys(ahx)-hbed-CC

    Icosapent ethyl

    Zanubrutinib

    Faricimab

    Ciltacabtagene autoleucel

    Belumosudil

    Estetrol monohydrate

    Finerenone

    Fostemsavir

    Inclisiran

    Pegcetacoplan

    Pegvaliase

    Sacituzumab govitecan

    Trastuzumab deruxtecan

    Vericiguat

    Bufexamac

    Restricted Medicines

    Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.

    Molnupiravir; for use in the treatment of COVID-19

    Nirmatrelvir; for use in the treatment of COVID-19

    Ritonavir; for use in the treatment of COVID-19

    Pharmacy-only Medicines

    Folic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Folinic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    25 October 2022 (2022-go4386)

    Prescription Medicines

    Nitrofurantoin; except when supplied for oral use containing 100 mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16-65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.

    Naloxone; except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use.

    Levomefolic acid; for injection.

    Amivantamab

    Glu-urea-Lys(ahx)-hbed-CC

    Icosapent ethyl

    Zanubrutinib

    Faricimab

    Ciltacabtagene autoleucel

    Belumosudil

    Estetrol monohydrate

    Finerenone

    Fostemsavir

    Inclisiran

    Pegcetacoplan

    Pegvaliase

    Sacituzumab govitecan

    Trastuzumab deruxtecan

    Vericiguat

    Bufexamac

    Pharmacy-only Medicines

    Folic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Folinic acid: For oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    Levomefolic acid; for oral use in medicines containing more than 500 micrograms per recommended daily dose. When the medicine contains a combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.

    21 September 2022 (2022-go4004)

    Prescription Medicines

    Recombinant varicella zoster virus glycoprotein E antigen; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed the Vaccinator Foundation Course (or any equivalent training course approved by the Ministry of Health) and who complies with the immunisation standards of the Ministry of Health (but excluding a vaccinator who has completed the Provisional Vaccinator Foundation Course).

    27 July 2022 (2022-go2856)

    Prescription Medicines

    Molnupiravir, except when specific elsewhere in this schedule

    Nirmatrelvir, except when specific elsewhere in this schedule

    Ritonavir, except when specific elsewhere in this schedule

    Restricted Medicines

    Molnupiravir, for use in the treatment of COVID-19

    Nirmatrelvir, for use in the treatment of COVID-19

    Ritonavir, for use in the treatment of COVID-19

    21 July 2022 (2022-go3006)

    Prescription Medicines

    Cardarine

    Arbutin; in oral preparations except herbal preparations containing 500 milligrams or less beta-arbutin per recommended daily dose.

    Ripretinib

    Faricimab

    Deutetrabenazine

    Eslicarbazepine

    Lemborexant

    Luspatercept

    Trabectedin

    Restricted Medicine

    Ibuprofen 300 milligrams in powder form; for oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units, and labelled for use in adults and children over 12 years of age.

    6 May 2022 (2022-go1725)

    Prescription Medicines

    Alanylglutamine

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use exceptwhen used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Cariprazine

    Casirivimab

    Cemiplimab

    Cilgavimab

    Elexacaftor

    Etesevimab

    Filgotinib

    Hyaluronidase

    Imdevimab

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Molnupiravir

    Onasemnogene abeparvovec

    Opicapone

    Nirmatrelvir

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Regdanvimab

    Risdiplam

    Sotrovimab

    Tixagevimab

    Trifarotene

    9 December 2021 (2021-go5269)

    Prescription Medicines

    Alanylglutamine

    Amethocaine; for internal use; for external use in medicines containing more than 10%; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; except when containing 2% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Benzocaine; except when specified elsewhere in this schedule; except in dermal preparations containing 2% or less of total anaesthetic substances; except in lozenges containing 30 milligrams or less of total anaesthetic substances per dosage unit; except when containing 20% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Cariprazine

    Elexacaftor

    Filgotinib

    Hyaluronidase

    Lignocaine; for injection except when used as a local anaesthetic in practice by a nurse whose scope of practice permits the performance of general nursing functions or by a podiatrist registered with the Podiatry Board or by a dental therapist or oral health therapist registered with the Dental Council; for ophthalmic use except when used in practice by an optometrist registered with the Optometrists and Dispensing Opticians Board; for oral use except in throat lozenges in medicines containing 30 milligrams or less per dose form; for external use in medicines containing more than 10%; except in throat sprays in medicines containing 2% or less; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Onasemnogene abeparvovec

    Opicapone

    Prilocaine; for injection except when used as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council; except when specified elsewhere in this schedule; except when containing 2.5% or less and used topically as a local anaesthetic in practice by a dental therapist or oral health therapist registered with the Dental Council.

    Trifarotene

    25 November 2021 (2021-go5108)

    Prescription Medicines

    Casirivimab

    Imdevimab

    Regdanvimab

    Sotrovimab

    Molnupiravir

    Tixagevimab

    Cilgavimab

    Etesevimab

    PF-07321332

    2 November 2021 (2021-go4592)

    Prescription Medicines

    Risdiplam

    Cemiplimab

    4 June 2021 (2021-go2170)

    Prescription Medicines

    Abemaciclib

    Acalabrutinib

    Alitretinoin

    Alkyl nitrites

    Alpelisib

    Artemisia annua extract

    Avelumab

    Avibactam

    Baloxavir marboxil

    Bamlanivimab

    Baricitinib

    Benralizumab

    Blinatumomab

    Brigatinib

    Brolucizumab

    Budesonide; except when specified elsewhere in this notice

    Cabotegravir

    Cedazuridine

    Cenegermin

    Cerliponase alfa

    Cilnidipine

    Codeine

    COVID-19 Vaccines; except when administered by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health

    Crisaborole

    Daratumumab

    Darolutamide

    Decitabine

    Dextromethorphan; except when specified elsewhere in this notice

    DMHA including the isomers 2-amino-6-methylheptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine)

    Doravirine

    Dulaglutide

    Durvalumab

    Enasidenib

    Entrectinib

    Esketamine

    Fluticasone; except when specified elsewhere in this notice

    Fosnetupitant

    Fremanezumab

    Galcanezumab

    Gilteritinib

    Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health

    Ibutamoren

    Indocyanine green

    Inotuzumab ozogamicin

    Isatuximab

    Isavuconazole

    Lanadelumab

    Larotrectinib

    Lifitegrast

    Linaclotide

    Lorlatinib

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist

    Meldonium

    Metamizole

    Methylphenylpiracetam

    Midostaurin

    Neratinib

    Niraparib

    Obeticholic acid

    Olaratumab

    Omberacetam

    Opium

    Ozanimod

    Phenylpiracetam

    Plitidepsin

    Polatuzumab vedotin

    Racetams; except when specified elsewhere in this notice

    Remdesivir

    Risankizumab

    Romosozumab

    Safinamide

    Siponimod

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Talazoparib

    Tafamidis

    Tezacaftor

    Tilmanocept

    Tivozanib

    Tucatinib

    Unifiram

    Upadacitinib

    Voglibose

    Voretigene neparvovec

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged six years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than five days’ supply.

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    Medicines for General Sale

    Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180 milligrams or less of fexofenadine hydrochloride with maximum daily dose of 180 milligrams when sold in the manufacturer’s original pack containing five dosage units or less and not more than five days’ supply.

    26 May 2021 (2021-go2045) – Corrigendum

    In the notice with the above heading, published in the New Zealand Gazette, 4 December 2020, Notice No. 2020-go5551 this corrigendum amends the notice by replacing the entry:

    DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine)

    With: DMHA including the isomers 2-amino-6-methylheptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexylamine)

    28 April 2021 (2021-go1534)

    Prescription Medicines

    Measles vaccine; except when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine; except when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine; except when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    4 March 2021 (2021-go609)

    Prescription Medicines

    Acalabrutinib

    Alitretinoin

    Brolucizumab

    Cabotegravir

    Cedazuridine

    Decitabine

    Enasidenib

    Fosnetupitant

    Fremanezumab

    Gilteritinib

    Indocyanine green

    Isatuximab

    Larotrectinib

    Ozanimod

    Siponimod

    Tafamidis

    Tucatinib

    Voretigene neparvovec

    Medicines for General Sale

    Fexofenadine; For the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply.

    Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180mg or less of fexofenadine hydrochloride with maximum daily dose of 180mg when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than 5 days’ supply.

    16 February 2021 (2021-go498)

    Prescription Medicines

    COVID-19 Vaccines; except when administered by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    17 December 2020 (2020-go5682)

    Prescription Medicines

    Bamlanivimab

    Dulaglutide

    Remdesivir

    4 December 2020 (2020-go5551)

    Prescription Medicines

    Abemaciclib

    Alkyl nitrites

    Alpelisib

    Artemisia annua extract

    Avelumab

    Avibactam

    Baricitinib

    Baloxavir marboxil

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Cenegermin

    Cerliponase alfa

    Cilnidipine

    Codeine

    Crisaborole

    Daratumumab

    Darolutamide

    Dextromethorphan; except when specified elsewhere in this notice.

    DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine).

    Doravirine

    Durvalumab

    Entrectinib

    Esketamine

    Galcanezumab

    Fluticasone; except when specified elsewhere in this notice.

    Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

    Ibutamoren

    Inotuzumab ozogamicin

    Isavuconazole

    Lanadelumab

    Lifitegrast

    Linaclotide

    Lorlatinib

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Meldonium

    Metamizole

    Methylphenylpiracetam

    Midostaurin

    Neratinib

    Niraparib

    Obeticholic acid

    Olaratumab

    Omberacetam

    Opium

    Phenylpiracetam

    Plitidepsin

    Polatuzumab vedotin

    Racetams; except when specified elsewhere in this notice.

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Talazoparib

    Tezacaftor

    Tilmanocept

    Tivozanib

    Unifiram

    UpadacitinibVoglibose

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    5 November 2020 (2020-go5093)

    Prescription Medicines

    Codeine

    28 October 2020 (2020-go4860)

    Prescription Medicines

    Measles vaccine; except when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine; except when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine; except when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    19 October 2020 (2020-go4832)

    Prescription Medicines

    Alpelisib

    Baloxavir marboxil

    Cilnidipine

    Darolutamide

    Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

    Lorlatinib

    Niraparib

    Talazoparib

    18 May 2020 (2020-go1183)

    Prescription Medicines

    Artemisia annua extract

    29 April 2020 (2020-go1806)

    Prescription Medicines

    Measles vaccine; except when specified elsewhere in this notice.

    Mumps vaccine; except when specified elsewhere in this notice.

    Rubella vaccine; except when specified elsewhere in this notice.

    Pharmacy-only Medicines

    Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    20 March 2020 (2020-go1191)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Cerliponase alfa

    Crisaborole

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice.

    Durvalumab

    Fluticasone; except when specified elsewhere in this notice.

    Ibutamoren

    Inotuzumab ozogamicin

    Lanadelumab

    Lifitegrast

    Linaclotide

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Polatuzumab vedotin

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Tilmanocept

    Tivozanib

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    6 March 2020 (2020-go1038)

    Prescription Medicines

    Abemaciclib

    Alkyl nitrites; except when specified elsewhere in the schedule.

    Aniracetam

    Avibactam

    Bilastine; except when specified elsewhere in this notice.

    Cenegermin

    Coluracetam

    Dimiracetam

    DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine).

    Doravirine

    Entrectinib

    Esketamine

    Fasoracetam

    Galcanezumab

    Influenza vaccine; except when administered to a person 13 years of age or over by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

    Isavuconazole

    Lanadelumab

    Meldonium

    Metamizole

    Methylphenylpiracetam

    Nebracetam

    Nefiracetam

    Omberacetam

    Oxiracetam

    Phenylpiracetam

    Plitidepsin

    Pramiracetam

    Racetams; except when specified elsewhere in this notice.

    Rolziracetam

    Seletracetam

    Semaglutide

    Sunifiram

    Unifiram

    Upadacitinib

    Voglibose

    Pharmacy-only Medicines

    Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

    19 December 2019 (2019-go5772)

    Prescription Medicines

    Polatuzumab vedotin

    1 November 2019 (2019-go5030)

    Prescription Medicines

    Measles vaccine; except when specified elsewhere in this notice.

    Mumps vaccine; except when specified elsewhere in this notice.

    Rubella vaccine; except when specified elsewhere in this notice.

    Pharmacy-only Medicines

    Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    20 September 2019 (2019-go4411)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Cerliponase alfa

    Crisaborole

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice.

    Durvalumab

    Fluticasone; except when specified elsewhere in this notice.

    Ibutamoren

    Inotuzumab ozogamicin

    Lanadelumab

    Lifitegrast

    Linaclotide

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Tilmanocept

    Tivozanib

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    12 July 2019 (2019-go3281)

    Prescription Medicines

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Crisaborole

    Fluticasone; except when specified elsewhere in this notice.

    Lanadelumab

    Romosozumab

    Safinamide

    Tilmanocept

    Tivozanib

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    24 June 2019 (2019-go2911)

    Prescription Medicines

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    25 February 2019 (2019-go841)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Cerliponase alfa

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice.

    Durvalumab

    Ibutamoren

    Inotuzumab ozogamicin

    Lifitegrast

    Linaclotide

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Risankizumab

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    4 March 2021 (2021-go609)

    Prescription Medicines

    Acalabrutinib

    Alitretinoin

    Brolucizumab

    Cabotegravir

    Cedazuridine

    Decitabine

    Enasidenib

    Fosnetupitant

    Fremanezumab

    Gilteritinib

    Indocyanine green

    Isatuximab

    Larotrectinib

    Ozanimod

    Siponimod

    Tafamidis

    Tucatinib

    Voretigene neparvovec

    Medicines for General Sale

    Fexofenadine; For the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 20 dosage units or less and not more than 10 days’ supply.

    Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in tablets containing 180mg or less of fexofenadine hydrochloride with maximum daily dose of 180mg when sold in the manufacturer’s original pack containing 5 dosage units or less and not more than 5 days’ supply.

    16 February 2021 (2021-go498)

    Prescription Medicines

    COVID-19 Vaccines; except when administered by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    17 December 2020 (2020-go5682)

    Prescription Medicines

    Bamlanivimab

    Dulaglutide

    Remdesivir

    4 December 2020 (2020-go5551)

    Prescription Medicines

    Abemaciclib

    Alkyl nitrites

    Alpelisib

    Artemisia annua extract

    Avelumab

    Avibactam

    Baricitinib

    Baloxavir marboxil

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Cenegermin

    Cerliponase alfa

    Cilnidipine

    Codeine

    Crisaborole

    Daratumumab

    Darolutamide

    Dextromethorphan; except when specified elsewhere in this notice.

    DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine).

    Doravirine

    Durvalumab

    Entrectinib

    Esketamine

    Galcanezumab

    Fluticasone; except when specified elsewhere in this notice.

    Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

    Ibutamoren

    Inotuzumab ozogamicin

    Isavuconazole

    Lanadelumab

    Lifitegrast

    Linaclotide

    Lorlatinib

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Meldonium

    Metamizole

    Methylphenylpiracetam

    Midostaurin

    Neratinib

    Niraparib

    Obeticholic acid

    Olaratumab

    Omberacetam

    Opium

    Phenylpiracetam

    Plitidepsin

    Polatuzumab vedotin

    Racetams; except when specified elsewhere in this notice.

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Talazoparib

    Tezacaftor

    Tilmanocept

    Tivozanib

    Unifiram

    UpadacitinibVoglibose

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    5 November 2020 (2020-go5093)

    Prescription Medicines

    Codeine

    28 October 2020 (2020-go4860)

    Prescription Medicines

    Measles vaccine; except when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine; except when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine; except when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    19 October 2020 (2020-go4832)

    Prescription Medicines

    Alpelisib

    Baloxavir marboxil

    Cilnidipine

    Darolutamide

    Human papillomavirus vaccine; except when administered by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health.

    Lorlatinib

    Niraparib

    Talazoparib

    18 May 2020 (2020-go1183)

    Prescription Medicines

    Artemisia annua extract

    29 April 2020 (2020-go1806)

    Prescription Medicines

    Measles vaccine; except when specified elsewhere in this notice.

    Mumps vaccine; except when specified elsewhere in this notice.

    Rubella vaccine; except when specified elsewhere in this notice.

    Pharmacy-only Medicines

    Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health.

    20 March 2020 (2020-go1191)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice.

    Cerliponase alfa

    Crisaborole

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice.

    Durvalumab

    Fluticasone; except when specified elsewhere in this notice.

    Ibutamoren

    Inotuzumab ozogamicin

    Lanadelumab

    Lifitegrast

    Linaclotide

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Polatuzumab vedotin

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Tilmanocept

    Tivozanib

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over.

    Paracetamol; in modified-release forms containing 665 milligrams or less.

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril).

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose).

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams.

    6 March 2020 (2019-go1038)

    Prescription medicines

    Abemaciclib

    Alkyl nitrites; except when specified elsewhere in the schedule

    Aniracetam

    Avibactam

    Bilastine; except when specified elsewhere in this notice

    Cenegermin

    Coluracetam

    Dimiracetam

    DMHA including the isomers 2-amino-6-methylhelptane (also known as 1,5-dimethylhexylamine, and octodrine) and 2-amino-5-methylheptane (also known as 1,4-dimethylhexamine)

    Doravirine

    Entrectinib

    Esketamine

    Fasoracetam

    Galcanezumab

    Influenza vaccine; except when administered to a person 13 years of age or over by a registered pharmacist or registered intern pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health

    Isavuconazole

    Lanadelumab

    Meldonium

    Metamizole

    Methylphenylpiracetam

    Nebracetam

    Nefiracetam

    Omberacetam

    Oxiracetam

    Phenylpiracetam

    Plitidepsin

    Pramiracetam

    Racetams; except when specified elsewhere in this notice

    Rolziracetam

    Seletracetam

    Semaglutide

    Sunifiram

    Unifiram

    Upadacitinib

    Voglibose

    Pharmacy-only medicines

    Bilastine; in divided solid dosage forms for oral use containing 20 milligrams or less for the treatment of the symptoms of allergic rhinoconjuctivitis (seasonal and perennial) and urticaria.

    19 December 2019 (2019-go5772)

    Prescription Medicines

    Polatuzumab vedotin

    1 November 2019 (2019-go5030)

    Prescription Medicines

    Measles vaccine; except when specified elsewhere in this notice

    Mumps vaccine; except when specified elsewhere in this notice

    Rubella vaccine; except when specified elsewhere in this notice

    Pharmacy-only Medicines

    Measles vaccine when administered in combination with mumps and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health

    Mumps vaccine when administered in combination with measles and rubella vaccines in a combination product the supply of which the Minister of Health has given consent, by a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health

    Rubella vaccine when administered in combination with mumps and measles vaccines in a combination product the supply of which the Minister of Health has given consent, a vaccinator who has successfully completed a training course approved by the Ministry of Health and who complies with the immunisation standards of the Ministry of Health

    20 September 2019 (2019-go4411)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Brigatinib

    Budesonide; except when specified elsewhere in this notice

    Cerliponase alfa

    Crisaborole

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice

    Durvalumab

    Fluticasone; except when specified elsewhere in this notice

    Ibutamoren

    Inotuzumab ozogamicin

    Lanadelumab

    Lifitegrast

    Linaclotide

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Risankizumab

    Romosozumab

    Safinamide

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Tilmanocept

    Tivozanib

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over

    Paracetamol; in modified-release forms containing 665 milligrams or less

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose)

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams

    12 July 2019 (2019-go3281)

    Prescription Medicines

    Brigatinib

    Budesonide; except when specified elsewhere in this notice

    Crisaborole

    Fluticasone; except when specified elsewhere in this notice

    Lanadelumab

    Romosozumab

    Safinamide

    Tilmanocept

    Tivozanib

    Pharmacy-only Medicines

    Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 64 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms (200 micrograms per nostril)

    Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation with a maximum recommended daily dose of 200 micrograms (as a single dose)

    24 June 2019 (2019-go2911)

    Prescription Medicines

    Melatonin; except when supplied in medicines for oral use containing 3mg or less per immediate release dose unit, or 2mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.

    25 February 2019 (2019-go841)

    Prescription Medicines

    Avelumab

    Baricitinib

    Benralizumab

    Blinatumomab

    Cerliponase alfa

    Daratumumab

    Dextromethorphan; except when specified elsewhere in this notice

    Durvalumab

    Ibutamoren

    Inotuzumab ozogamicin

    Lifitegrast

    Linaclotide

    Midostaurin

    Neratinib

    Obeticholic acid

    Olaratumab

    Opium

    Risankizumab

    Squill

    Stenabolic (SR9009) and other synthetic REV-ERB agonists

    Tezacaftor

    Voxilaprevir

    Restricted Medicines

    Dextromethorphan; in liquid form when in packs containing not more than 600 milligrams and with a recommended daily dose of not more than 120 milligrams; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over

    Paracetamol; in modified-release forms containing 665 milligrams or less

    Pharmacy-only Medicines

    Paracetamol; in liquid form; in suppositories; in tablets or capsules containing 500 milligrams or less and in packs containing more than 10 grams and not more than 50 grams; in powder form containing not more than 1 gram per sachet and more than 10 grams per pack; except in tablets or capsules containing 500 milligrams or less and in packs containing not more than 10 grams; except in powder form in sachets containing 1 gram or less and in packs of not more than 10 grams

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /